nsi-189

  • Nootropics Coluracetam CAS 135463-81-9

    Being one of the newer entrants to the Racetam family of drugs, Coluracetam (buy from hhdpharm) was first registered with PubChem in 2005 by the Mitsubishi Tanabe Pharma Corporation and later handed off to BrainCells Inc, who has done a majority of the testing on it, including the Phase 2A trials which were completed in 2010 . Upon completion of the Phase 2A trials, BrainCells announced that Coluracetam showed promise as a treatment for Major Depressive Disorder co-morbid with Generalized Anxiety Disorder, but did not show significant results treating participants who only had one of those disorders. Coluracetam (buy from hhdpharm) appears to have two well-defined mechanisms of action; the first being high-affinity choline uptake, and the other being AMPA potentiation . As is the case with a few of the Racetams, Coluracetam has been show to facilitate AMPA potentiation which is known to increase alertness, memory, and learning capabilities. What is more intriguing about Coluracetam are its high-affinity choline uptake properties; choline uptake plays a crucial role in the Acetylcholine synthesis process in the brain by acting as a rate-limiter. This rate-limiting step allows the brain to convert choline into Acetylcholine in the neuron, and by increasing the high-affinity choline uptake the brain is more readily able to convert choline to Acetylcholine; by increasing the ability to convert choline to Acetylcholine, should in theory improve attention, memory, and wakefulness in humans.

    Email Details
  • NSI-189 Phosphate Freebase /NSI 189 Phosphate Base

    NSI-189 is neurogenic and nootropic research agent that was developed from nicotinamide and pyrazine. Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, it has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression. It is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer’s disease and age-related cognitive problems. NSI-189 is an experimental antidepressant. Neuralstem, Inc. is currently testing it for use in major depression, in addition to treating cognitive impairments, and brain degeneration. It may induce specific brain regeneration. NSI-189 is most likely selective only to two nervous system controlling regions in the brain (hippocampus, subventricular zone)

    Email Details
Get the latest price? We'll respond as soon as possible(within 12 hours)